CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向多发性骨髓瘤中的免疫突触

Targeting the immunological synapse in multiple myeloma.

血液系统恶性肿瘤治疗的创新方法：CRISPR 工程化微生物组沿肠-免疫轴在免疫治疗开发中的作用

Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunothera

TIM-3 在 AML 中：致病作用与治疗靶向性

TIM-3 in AML: pathogenic roles and therapeutic targetability.

单克隆丙种球蛋白病的奥德赛之旅：聚焦前驱病变及从 MGUS 和 SMM 向多发性骨髓瘤的进展，并简要概述新型治疗策略

An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of nove

超越 CRISPR：CAR-NK 细胞的下一代精准工程化以增强持久性、迁移与肿瘤清除

Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication.

下一代脐血扩增：以生物工程微环境弥合细胞剂量缺口与临床突破

"Next-Generation Cord Blood Expansion: Bridging the Cell Dose Gap with Bioengineered Niches and Clinical Breakthroughs".

减少 CAR-T 细胞治疗副作用的新兴策略：聚焦基因编辑与纳米技术

Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology.

CRISPR 工程化微生物组：活体疗法彻底改变血液肿瘤免疫治疗

CRISPR-engineered microbiome: living therapeutics revolutionize blood cancer immunotherapy.

CRISPR-Cas9 在白血病免疫治疗中的应用：CAR-T 细胞的精准工程化与肿瘤微环境调控

CRISPR-Cas9 in leukemia immunotherapy: precision engineering of CAR-T cells and tumor-microenvironment modulation.

揭示癌症的沉默破坏者：T 调节细胞作为免疫治疗中的治疗靶点

Unmasking cancer's silent saboteurs: T regulatory cells as therapeutic targets in immunotherapy.

靶向肿瘤浸润性调节性 T 细胞（Tregs）是癌症免疫治疗中一种有前景但复杂的策略。然而，其成功受到自身免疫风险、瘤内递送效率低下以及患者免疫异质性的限制。整合生物标志物指导的分层、单细胞和空间谱分析的精准策略可以提高选择性和治疗结局。识别肿瘤特异性 Treg 标志物，并将稳定的、具有抑制功能的 Treg 与更具可塑性或“脆弱”的亚群区分开来，对于推进靶向免疫治疗至关重要。对肿瘤驻留 Treg 进行部分功能重编程，而非将其完全清除，提供